Related references
Note: Only part of the references are listed.Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hiroya Hashizume et al.
CANCER RESEARCH (2010)
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting the ANGPT-TIE2 pathway in malignancy
Hanhua Huang et al.
NATURE REVIEWS CANCER (2010)
New treatment approaches in renal cell carcinoma
Gaetano Facchini et al.
ANTI-CANCER DRUGS (2009)
Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment
A. Constantinou et al.
BIOCONJUGATE CHEMISTRY (2009)
An efficient chemical approach to bispecific antibodies and antibodies of high valency
Julia I. Gavrilyuk et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Treatment in advanced colorectal cancer: what, when and how?
I. Chau et al.
BRITISH JOURNAL OF CANCER (2009)
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
Iris Helfrich et al.
CLINICAL CANCER RESEARCH (2009)
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
Konstantin J. Dedes et al.
EUROPEAN JOURNAL OF CANCER (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
M. K. Robinson et al.
BRITISH JOURNAL OF CANCER (2008)
Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer
Marianna Aita et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era
Fausto Petrelli et al.
ONCOLOGIST (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Chemically programmed antibodies:: Endothelin receptor targeting CovX-Bodies™
Venkata R. Doppalapudi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Bispecific antibodies: Molecules that enable novel therapeutic strategies
Nicolas Fischer et al.
PATHOBIOLOGY (2007)
The place of VEGF inhibition in the current management of renal cell carcinoma
P Nathan et al.
BRITISH JOURNAL OF CANCER (2006)
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy
C Rader et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
WS Moon et al.
MODERN PATHOLOGY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst
C Rader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
